The global Thrombogenic Agents market size was valued at US$ 617 million in 2024 and is forecast to a readjusted size of USD 790 million by 2031 with a CAGR of 3.6% during review period.
Thrombogenic agents are a type of medications that can promote blood clotting in blood vessels, leading to the formation of blood clots. These drugs can activate the coagulation system through different mechanisms of action, leading to platelet aggregation and fibrin formation, thereby triggering the formation of blood clots. According to their mechanisms of action, thrombogenic agents typically include antithrombin III dependent anticoagulants, vitamin K antagonists, thrombin direct inhibitors, Xa factor inhibitors, and other types. They are widely used in fields such as hemostasis, tumor treatment, cardiovascular disease treatment, scientific research, and drug development.
The global thrombogenic agents market continues to expand, with the rise in the incidence rate of cardiovascular diseases, technological progress and the impact of patented drugs as the main driving factors. Thrombogenic agents may be used in the treatment of cardiovascular diseases such as coronary heart disease, myocardial infarction, and stroke, such as controlling bleeding during surgery or promoting repair after vascular injury, thereby driving market growth. The development of new treatment technologies and drugs has provided more application scenarios and opportunities for thrombogenic agents. The patent protected thrombogenic agents have attracted the attention and investment of many enterprises due to their uniqueness and effectiveness, further promoting the development of the market. The market competition is fierce and there are many participants. Internationally renowned pharmaceutical companies such as Bayer and Pfizer have multiple products and patented technologies in the field of thrombogenic agents, and have strong capabilities and rich experience in research and development, production, and sales. At the same time, domestic companies such as Zhongbao Pharmaceutical and Tiancheng Pharmaceutical are also increasing their R&D investment, continuously improving product quality and technological level, and gradually occupying a certain market share. The risk of side effects and competition from alternative products are the main limiting factors in the market. In the future, advances in biotechnology and genetic engineering will drive the development of novel thrombogenic agents. Personalized treatment plans will become an important direction for future development based on the needs of different patients.
This report is a detailed and comprehensive analysis for global Thrombogenic Agents market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Thrombogenic Agents market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2020-2031
Global Thrombogenic Agents market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2020-2031
Global Thrombogenic Agents market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2020-2031
Global Thrombogenic Agents market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Thrombogenic Agents
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Thrombogenic Agents market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Merck, Pfizer, BristolMyers Squibb, AbbVie, Sanofi, Johnson And Johnson, Boehringer Ingelheim, Amgen, Novo Nordisk, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
Thrombogenic Agents market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Antithrombin 鈪� Dependent Anticoagulants
Vitamin K Antagonists
Direct Thrombin Inhibitors
Factor Xa Inhibitors
Others
麻豆原创 segment by Application
Stop Bleeding
Tumor Treatment
Cardiovascular Disease Treatment
Research And Drug Development
Others
Major players covered
Roche
Merck
Pfizer
BristolMyers Squibb
AbbVie
Sanofi
Johnson And Johnson
Boehringer Ingelheim
Amgen
Novo Nordisk
Zhongbao Pharmaceutical
Tiancheng Pharmaceutical Group
Chongqing Laimei Pharmaceutical
Nuokang Pharmaceutical Group
Shanghai RAAS Blood Products
Shandong Taibang Biotechnology
Boya Biopharmaceutical
Chongqing Dikang Yangtze River Pharmaceutical
Wuzhong Medicine Suzhou Pharmaceutical
Jiangsu Yabang Aipson Pharmaceutical
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Thrombogenic Agents product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Thrombogenic Agents, with price, sales quantity, revenue, and global market share of Thrombogenic Agents from 2020 to 2025.
Chapter 3, the Thrombogenic Agents competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Thrombogenic Agents breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Thrombogenic Agents market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Thrombogenic Agents.
Chapter 14 and 15, to describe Thrombogenic Agents sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Thrombogenic Agents Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Antithrombin 鈪� Dependent Anticoagulants
1.3.3 Vitamin K Antagonists
1.3.4 Direct Thrombin Inhibitors
1.3.5 Factor Xa Inhibitors
1.3.6 Others
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Thrombogenic Agents Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Stop Bleeding
1.4.3 Tumor Treatment
1.4.4 Cardiovascular Disease Treatment
1.4.5 Research And Drug Development
1.4.6 Others
1.5 Global Thrombogenic Agents 麻豆原创 Size & Forecast
1.5.1 Global Thrombogenic Agents Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Thrombogenic Agents Sales Quantity (2020-2031)
1.5.3 Global Thrombogenic Agents Average Price (2020-2031)
2 Manufacturers Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Thrombogenic Agents Product and Services
2.1.4 Roche Thrombogenic Agents Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Roche Recent Developments/Updates
2.2 Merck
2.2.1 Merck Details
2.2.2 Merck Major Business
2.2.3 Merck Thrombogenic Agents Product and Services
2.2.4 Merck Thrombogenic Agents Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Merck Recent Developments/Updates
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer Thrombogenic Agents Product and Services
2.3.4 Pfizer Thrombogenic Agents Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Pfizer Recent Developments/Updates
2.4 BristolMyers Squibb
2.4.1 BristolMyers Squibb Details
2.4.2 BristolMyers Squibb Major Business
2.4.3 BristolMyers Squibb Thrombogenic Agents Product and Services
2.4.4 BristolMyers Squibb Thrombogenic Agents Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 BristolMyers Squibb Recent Developments/Updates
2.5 AbbVie
2.5.1 AbbVie Details
2.5.2 AbbVie Major Business
2.5.3 AbbVie Thrombogenic Agents Product and Services
2.5.4 AbbVie Thrombogenic Agents Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 AbbVie Recent Developments/Updates
2.6 Sanofi
2.6.1 Sanofi Details
2.6.2 Sanofi Major Business
2.6.3 Sanofi Thrombogenic Agents Product and Services
2.6.4 Sanofi Thrombogenic Agents Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Sanofi Recent Developments/Updates
2.7 Johnson And Johnson
2.7.1 Johnson And Johnson Details
2.7.2 Johnson And Johnson Major Business
2.7.3 Johnson And Johnson Thrombogenic Agents Product and Services
2.7.4 Johnson And Johnson Thrombogenic Agents Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Johnson And Johnson Recent Developments/Updates
2.8 Boehringer Ingelheim
2.8.1 Boehringer Ingelheim Details
2.8.2 Boehringer Ingelheim Major Business
2.8.3 Boehringer Ingelheim Thrombogenic Agents Product and Services
2.8.4 Boehringer Ingelheim Thrombogenic Agents Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Boehringer Ingelheim Recent Developments/Updates
2.9 Amgen
2.9.1 Amgen Details
2.9.2 Amgen Major Business
2.9.3 Amgen Thrombogenic Agents Product and Services
2.9.4 Amgen Thrombogenic Agents Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Amgen Recent Developments/Updates
2.10 Novo Nordisk
2.10.1 Novo Nordisk Details
2.10.2 Novo Nordisk Major Business
2.10.3 Novo Nordisk Thrombogenic Agents Product and Services
2.10.4 Novo Nordisk Thrombogenic Agents Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 Novo Nordisk Recent Developments/Updates
2.11 Zhongbao Pharmaceutical
2.11.1 Zhongbao Pharmaceutical Details
2.11.2 Zhongbao Pharmaceutical Major Business
2.11.3 Zhongbao Pharmaceutical Thrombogenic Agents Product and Services
2.11.4 Zhongbao Pharmaceutical Thrombogenic Agents Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 Zhongbao Pharmaceutical Recent Developments/Updates
2.12 Tiancheng Pharmaceutical Group
2.12.1 Tiancheng Pharmaceutical Group Details
2.12.2 Tiancheng Pharmaceutical Group Major Business
2.12.3 Tiancheng Pharmaceutical Group Thrombogenic Agents Product and Services
2.12.4 Tiancheng Pharmaceutical Group Thrombogenic Agents Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.12.5 Tiancheng Pharmaceutical Group Recent Developments/Updates
2.13 Chongqing Laimei Pharmaceutical
2.13.1 Chongqing Laimei Pharmaceutical Details
2.13.2 Chongqing Laimei Pharmaceutical Major Business
2.13.3 Chongqing Laimei Pharmaceutical Thrombogenic Agents Product and Services
2.13.4 Chongqing Laimei Pharmaceutical Thrombogenic Agents Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.13.5 Chongqing Laimei Pharmaceutical Recent Developments/Updates
2.14 Nuokang Pharmaceutical Group
2.14.1 Nuokang Pharmaceutical Group Details
2.14.2 Nuokang Pharmaceutical Group Major Business
2.14.3 Nuokang Pharmaceutical Group Thrombogenic Agents Product and Services
2.14.4 Nuokang Pharmaceutical Group Thrombogenic Agents Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.14.5 Nuokang Pharmaceutical Group Recent Developments/Updates
2.15 Shanghai RAAS Blood Products
2.15.1 Shanghai RAAS Blood Products Details
2.15.2 Shanghai RAAS Blood Products Major Business
2.15.3 Shanghai RAAS Blood Products Thrombogenic Agents Product and Services
2.15.4 Shanghai RAAS Blood Products Thrombogenic Agents Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.15.5 Shanghai RAAS Blood Products Recent Developments/Updates
2.16 Shandong Taibang Biotechnology
2.16.1 Shandong Taibang Biotechnology Details
2.16.2 Shandong Taibang Biotechnology Major Business
2.16.3 Shandong Taibang Biotechnology Thrombogenic Agents Product and Services
2.16.4 Shandong Taibang Biotechnology Thrombogenic Agents Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.16.5 Shandong Taibang Biotechnology Recent Developments/Updates
2.17 Boya Biopharmaceutical
2.17.1 Boya Biopharmaceutical Details
2.17.2 Boya Biopharmaceutical Major Business
2.17.3 Boya Biopharmaceutical Thrombogenic Agents Product and Services
2.17.4 Boya Biopharmaceutical Thrombogenic Agents Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.17.5 Boya Biopharmaceutical Recent Developments/Updates
2.18 Chongqing Dikang Yangtze River Pharmaceutical
2.18.1 Chongqing Dikang Yangtze River Pharmaceutical Details
2.18.2 Chongqing Dikang Yangtze River Pharmaceutical Major Business
2.18.3 Chongqing Dikang Yangtze River Pharmaceutical Thrombogenic Agents Product and Services
2.18.4 Chongqing Dikang Yangtze River Pharmaceutical Thrombogenic Agents Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.18.5 Chongqing Dikang Yangtze River Pharmaceutical Recent Developments/Updates
2.19 Wuzhong Medicine Suzhou Pharmaceutical
2.19.1 Wuzhong Medicine Suzhou Pharmaceutical Details
2.19.2 Wuzhong Medicine Suzhou Pharmaceutical Major Business
2.19.3 Wuzhong Medicine Suzhou Pharmaceutical Thrombogenic Agents Product and Services
2.19.4 Wuzhong Medicine Suzhou Pharmaceutical Thrombogenic Agents Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.19.5 Wuzhong Medicine Suzhou Pharmaceutical Recent Developments/Updates
2.20 Jiangsu Yabang Aipson Pharmaceutical
2.20.1 Jiangsu Yabang Aipson Pharmaceutical Details
2.20.2 Jiangsu Yabang Aipson Pharmaceutical Major Business
2.20.3 Jiangsu Yabang Aipson Pharmaceutical Thrombogenic Agents Product and Services
2.20.4 Jiangsu Yabang Aipson Pharmaceutical Thrombogenic Agents Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.20.5 Jiangsu Yabang Aipson Pharmaceutical Recent Developments/Updates
3 Competitive Environment: Thrombogenic Agents by Manufacturer
3.1 Global Thrombogenic Agents Sales Quantity by Manufacturer (2020-2025)
3.2 Global Thrombogenic Agents Revenue by Manufacturer (2020-2025)
3.3 Global Thrombogenic Agents Average Price by Manufacturer (2020-2025)
3.4 麻豆原创 Share Analysis (2024)
3.4.1 Producer Shipments of Thrombogenic Agents by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2024
3.4.2 Top 3 Thrombogenic Agents Manufacturer 麻豆原创 Share in 2024
3.4.3 Top 6 Thrombogenic Agents Manufacturer 麻豆原创 Share in 2024
3.5 Thrombogenic Agents 麻豆原创: Overall Company Footprint Analysis
3.5.1 Thrombogenic Agents 麻豆原创: Region Footprint
3.5.2 Thrombogenic Agents 麻豆原创: Company Product Type Footprint
3.5.3 Thrombogenic Agents 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Thrombogenic Agents 麻豆原创 Size by Region
4.1.1 Global Thrombogenic Agents Sales Quantity by Region (2020-2031)
4.1.2 Global Thrombogenic Agents Consumption Value by Region (2020-2031)
4.1.3 Global Thrombogenic Agents Average Price by Region (2020-2031)
4.2 North America Thrombogenic Agents Consumption Value (2020-2031)
4.3 Europe Thrombogenic Agents Consumption Value (2020-2031)
4.4 Asia-Pacific Thrombogenic Agents Consumption Value (2020-2031)
4.5 South America Thrombogenic Agents Consumption Value (2020-2031)
4.6 Middle East & Africa Thrombogenic Agents Consumption Value (2020-2031)
5 麻豆原创 Segment by Type
5.1 Global Thrombogenic Agents Sales Quantity by Type (2020-2031)
5.2 Global Thrombogenic Agents Consumption Value by Type (2020-2031)
5.3 Global Thrombogenic Agents Average Price by Type (2020-2031)
6 麻豆原创 Segment by Application
6.1 Global Thrombogenic Agents Sales Quantity by Application (2020-2031)
6.2 Global Thrombogenic Agents Consumption Value by Application (2020-2031)
6.3 Global Thrombogenic Agents Average Price by Application (2020-2031)
7 North America
7.1 North America Thrombogenic Agents Sales Quantity by Type (2020-2031)
7.2 North America Thrombogenic Agents Sales Quantity by Application (2020-2031)
7.3 North America Thrombogenic Agents 麻豆原创 Size by Country
7.3.1 North America Thrombogenic Agents Sales Quantity by Country (2020-2031)
7.3.2 North America Thrombogenic Agents Consumption Value by Country (2020-2031)
7.3.3 United States 麻豆原创 Size and Forecast (2020-2031)
7.3.4 Canada 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Mexico 麻豆原创 Size and Forecast (2020-2031)
8 Europe
8.1 Europe Thrombogenic Agents Sales Quantity by Type (2020-2031)
8.2 Europe Thrombogenic Agents Sales Quantity by Application (2020-2031)
8.3 Europe Thrombogenic Agents 麻豆原创 Size by Country
8.3.1 Europe Thrombogenic Agents Sales Quantity by Country (2020-2031)
8.3.2 Europe Thrombogenic Agents Consumption Value by Country (2020-2031)
8.3.3 Germany 麻豆原创 Size and Forecast (2020-2031)
8.3.4 France 麻豆原创 Size and Forecast (2020-2031)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Russia 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Italy 麻豆原创 Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific Thrombogenic Agents Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Thrombogenic Agents Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Thrombogenic Agents 麻豆原创 Size by Region
9.3.1 Asia-Pacific Thrombogenic Agents Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Thrombogenic Agents Consumption Value by Region (2020-2031)
9.3.3 China 麻豆原创 Size and Forecast (2020-2031)
9.3.4 Japan 麻豆原创 Size and Forecast (2020-2031)
9.3.5 South Korea 麻豆原创 Size and Forecast (2020-2031)
9.3.6 India 麻豆原创 Size and Forecast (2020-2031)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2020-2031)
9.3.8 Australia 麻豆原创 Size and Forecast (2020-2031)
10 South America
10.1 South America Thrombogenic Agents Sales Quantity by Type (2020-2031)
10.2 South America Thrombogenic Agents Sales Quantity by Application (2020-2031)
10.3 South America Thrombogenic Agents 麻豆原创 Size by Country
10.3.1 South America Thrombogenic Agents Sales Quantity by Country (2020-2031)
10.3.2 South America Thrombogenic Agents Consumption Value by Country (2020-2031)
10.3.3 Brazil 麻豆原创 Size and Forecast (2020-2031)
10.3.4 Argentina 麻豆原创 Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa Thrombogenic Agents Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Thrombogenic Agents Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Thrombogenic Agents 麻豆原创 Size by Country
11.3.1 Middle East & Africa Thrombogenic Agents Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Thrombogenic Agents Consumption Value by Country (2020-2031)
11.3.3 Turkey 麻豆原创 Size and Forecast (2020-2031)
11.3.4 Egypt 麻豆原创 Size and Forecast (2020-2031)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2020-2031)
11.3.6 South Africa 麻豆原创 Size and Forecast (2020-2031)
12 麻豆原创 Dynamics
12.1 Thrombogenic Agents 麻豆原创 Drivers
12.2 Thrombogenic Agents 麻豆原创 Restraints
12.3 Thrombogenic Agents Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Thrombogenic Agents and Key Manufacturers
13.2 Manufacturing Costs Percentage of Thrombogenic Agents
13.3 Thrombogenic Agents Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Thrombogenic Agents Typical Distributors
14.3 Thrombogenic Agents Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Roche
Merck
Pfizer
BristolMyers Squibb
AbbVie
Sanofi
Johnson And Johnson
Boehringer Ingelheim
Amgen
Novo Nordisk
Zhongbao Pharmaceutical
Tiancheng Pharmaceutical Group
Chongqing Laimei Pharmaceutical
Nuokang Pharmaceutical Group
Shanghai RAAS Blood Products
Shandong Taibang Biotechnology
Boya Biopharmaceutical
Chongqing Dikang Yangtze River Pharmaceutical
Wuzhong Medicine Suzhou Pharmaceutical
Jiangsu Yabang Aipson Pharmaceutical
听
听
*If Applicable.
